Care and Management of the Patient with Multiple Sclerosis (3 CEUs)
Written By: Kristi Hudson RN MSN CCRN
Written: 9/9/06
Updated: August 31, 2009
Course Description:
This course is designed to provide the student an overview of the care and management of the patient with Multiple Sclerosis (MS). Focus will be placed on pathophysiology, cause, onset, signs and symptoms and diagnosis of this disease process. Emphasis on medical and nursing treatment options will be the final focus of this course.
Course Objectives:
Upon completion of this course the student will be able to:
Describe the pathophysiology that leads to MS
List known causes of the MS
Explain the process for diagnosing MS
Discuss pharmacological treatment options for patients with MS
Differentiate the four types of MS
State the factors known to exacerbate MS
List NANDA nursing diagnosis’ appropriate for the patient with MS
Describe important patient/family teaching necessities
Pathophysiology:
Multiple sclerosis (MS); which is thought to be a chronic disease in which the body’s immune system “attacks” the myelin sheath (a fatty substance that covers the axons of nerve cells). This in turns disrupts proper nerve conduction which causes debilitating affects to the central nervous system.
The inflammation, scarring or injury to the myelin sheath causes slowing or blockage of nerve signals that control muscle coordination, strength, sensation and vision.
In addition to myelin sheath deterioration; certain T cells (white blood cells that play a role in cell-mediated immunity) play a key role in the development of MS. Under normal circumstances, T cells can distinguish what is foreign in the body and what is not, but in cases of MS, these T cells view health body tissues as “foreign” and attack them as if they were an invading virus (this triggers the inflammatory process and causes leakage in the blood-brain barrier).
Cause:
The exact cause of MS is unknown but most researchers believe that the disease is an autoimmune disease. Although the actual triggers to the immune system have not been proven, most scientists agree that there are several factors involved. These factors include:
Genetics
Gender
Environmental Triggers (viruses, trauma and heavy metals)
Onset:
Onset of MS most often occurs between the ages of 20 and 40. The initial symptoms of this disease process are blurred or double vision, red-green color distortion, or even blindness in one eye. These visual symptoms are often followed by complaints muscle weakness in the extremities and difficulty with coordination and balance. If these musculoskeletal symptoms are severe enough, partial or complete paralysis can occur.
Signs and Symptoms:
Signs and symptoms of MS vary depending on the location or affected myelin sheath damage. Common presenting symptoms include:
Numbness or weakness in one or more limbs (typically occurs on one side).
Partial or complete loss of vision.
Double or blurred vision.
Tingling or pain in numb areas of the body.
Electrical shock sensations that occur with certain head movements.
Diagnosis of MS can be difficult in the early stages but evidence of symptoms characteristic of MS that involve two different anatomical locations occurring at least 30 days apart) is thought to be highly suggestive of the disease. Other diagnostic testing includes:
MRI scan provides a detailed view of the brain and spine, including demyelinating lesions or plaque.
Lumbar puncture checks cerebral spinal fluid for signs of the disease such as chronic inflammation or oligoclonal bands which are found in 85% to 95% of all patients with MS.
Visual Evoked Potential (VEPs) or Somatosensory Evoked Potentials (SEPs) that show decreased activity of the optic nerve or sensory nerves can also assist in the diagnosis of MS.
Myelin Oligondendrocyte Glycoprotein (MOG) is a test that measures glycoproteins that are thought to be important in the myelinization of nerves in the central nervous system (this test in not currently a mainstay for diagnosing MS but thought to a test of the future).
Four categories of MS
Type
Description
Relapsing-remitting MS (RRMS: 80% of all cases).
Recurrent neurological dysfunction that evolves over days or weeks. These attacks may be followed by complete, partial or no recovery. There is no progression of symptoms between attacks and this pattern is often seen in the early course of the disease.
Secondary Progressive MS
Gradual neurological deterioration with or without an acute relapse. Minor remissions and plateaus (for patients who previously had RRMS), are noted.
Progressive Relapsing MS
From the onset there is a gradual progression of worsening neurological dysfunction and disability. There is no stabilization of the disease process.
Primary Progressive MS
A pattern of neurological deterioration with superimposed relapse periods noted.
Drug Treatment Options
Category of MS
Drug
Dose
Side Effects
Relapsing-remitting MS
Interferonß-1B (Betaseron.)
FDA approved 1993
8 million IU SC qid
Flu like symptoms and injection site reaction
Interferonß-1a (Avonex.)
FDA approved
1996
30 mcg. IM Q Week
Flu like symptoms, muscle aches, elevated liver enzymes
Gatiramer Acetate (Copaxone)/
FDA approved
1996
20 mcg. SC Q Day
Injection site reaction, anxiety, chest tightness, SOB and flushing.
Secondary Progressive MS
Interferonß-1B (Betaseron.)
FDA approved 1993
8 million IU SC qid
Flu like symptoms and injection site reaction
Mitoxantrone
Several reported med schedules.
Amenorrhea, alopecia, NVD, UTI, decreased WBC
Progressive Relapsing MS
No medications offer symptom management
Primary Progressive MS
Methylprednisolone
Several reported schedules such as 1000 mg IV QD for 3 days followed by a tapering prednisone dose
Decreased K+, fluid retention, gastric irritation and weight gain
Symptom Management for MS
Problem
Non-pharmacologic therapy
Drugs
(PO)
Side Effects
Spasticity
Physical therapy and exercise
1. Baclofen 5-20 mg bid
2. Tizanidine 4-8 mg tid
3. Diazepam 2-20 mg bid
4. Dantrolene 25-100 mg bid
1. Exacerbates muscle weakness.
2, 3 and 4 are used for nocturnal spasticity and can also exacerbate muscle weakness.
Sensory Symptoms (burning, itching)
None
Amitriptyline 75-100 mg in divided doses or 50-150 mg Q HS
Dry mouth, tachycardia, arrhythmias, sedation
Urinary (hyper-reflexia, frequency, incontinence)
Intermittent self catheterization
Oxybutynin 2.5 -5 mg. bid or tid
or
Prazosin 0.5 QD
Dry mouth, tachycardia and hypotension
Tremors/Ataxia
Exercise program and gait training
Clonazepam 0.5 mg QD (can be given up to tid)
Sedation, muscle weakness
Neuropathic pain
None
Neurontin 100 mg tid or qid
Titrate slowly to decrease sedative effect.
Fatigue
Rule out cause, exercise program
1. Amantadine 100-200 mg bid
2. Modafinil 100-200 mg bid
1. Depression irritability anorexia
2. Headache, arrhythmias, nausea
Depression
Counseling, psychotherapy.
1. Citalopram 20 mg qid
2. Sertraline 50 mgQD
3. Fluoxetine 20 mg QD (titrate to effect)
1. Tremors, somnolence, insomnia
2. Headache, tremors, insomnia, agitation
3. Anxiety, insomnia, palpitations NVD
Nursing Management:
Patient education regarding MS and factors that are related to relapse are important nursing interventions. The following are exacerbating factors and should be avoided:
Undue fatigue or excessive exertion
Overheating or excessive chilling (exposure to cold)
Infections
Hot baths
Fever
Emotional stress
Pregnancy (should be discussed with physician to weigh the degree of expected problems prior to making decision to become pregnant)
Nursing Diagnosis:
Knowledge deficit
Impaired mobility
Self care deficit
High risk for injury
Self concept disturbance
Impaired home maintenance
Note: For patients with advanced disease, nursing education will include the use of braces, canes and if necessary confinement to a wheelchair, modifying lifestyles to maintain optimal independence.